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Background: The hepatitis C virus (HCV) has six major genotypes and more than 100 subtypes, and the determination of the responsible 
genotype, collection of epidemiological data, tailoring antiviral therapy, and prediction of prognosis have an important place in disease 
management.
Objectives: The aim of the present study was to determine the distribution of HCV genotypes across geographic regions and compare 
these data with those obtained from other geographic locations.
Patients and Methods: The HCV genotypes were identified in HCV RNA positive blood samples, obtained from different centers. The HCV 
genotype was determined using molecular methods [Real-Time Polymerase Chain Reaction (RT-PCR)] in 313 patients, who were found to be 
positive for HCV RNA. The presence of HCV RNA was investigated using the RT-PCR method in serum samples delivered to the Microbiology 
Laboratory at Kahramanmaras Necip Fazıl City Hospital, Kahramanmaras, Turkey, from the centers located in Kahramanmaras City center 
and peripheral districts of the province, between March 2010 and August 2014. The HCV genotype analysis was performed in HCV RNA 
positive samples, using RT-PCR reagents kit. Urine samples from the patients were tested for amphetamine with an Amphetamines II 
(AMPS2) kit, cocaine was tested with a Cocaine II (COC2) kit, opiates were tested with an Opiates II (OPI2) kit, and cannabinoids were tested 
with a Cannabinoids II (THC2) kit in Roche/Hitachi Cobas c501 device.
Results: The blood samples collected from 313 patients were included in the study. Of these patients, 212 (67.7%) were male and 101 (32.3%) 
were female. The mean age of the patients was 41.29 ± 20.32 years. In terms of HCV genotype distribution, 162 patients (51.7%) had genotype 
1, 144 patients (46%) had genotype 3, four patients (1.3%) had genotype 2, and three patients (1%) had genotype 4. The results of urine drug 
tests were available in only 65 patients (20.2%). Of these, 61 (93.8%) patients had HCV genotype 3.
Conclusions: In conclusion, the prevalence of HCV genotype 1 was 51.7%, which was lower than the rates reported in other studies in Turkey, 
while the prevalence of HCV genotype 3 was 46%, which was remarkably higher than the reported Turkish data. In addition, the prevalence 
rate for genotype 3 reported in the present study is the highest that has ever been reported in the literature.
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1. Background
It is estimated that approximately 170 - 300 million 
people worldwide are infected with the hepatitis C virus 
(HCV). The HCV accounts for 20% of all cases with acute 
viral hepatitis and 70% of all cases with chronic viral hep-
atitis (1). The infection with HCV is associated with high 
morbidity and mortality, due to the development of cir-
rhosis and hepatocellular carcinoma, and approximately 
350000 people die every year, globally, due to HCV infec-
tion (2). The frequencies of HCV genotypes in different 
geographic regions change over time, depending on the 
study population, the route of infection, and virus muta-
tion. The HCV genotype 1b is the predominant subtype in 
Turkey, Russia, Moldova, and Uzbekistan, while genotype 
4 is predominant in Saudi Arabia, Iraq, Qatar, Bahrain, Ku-
wait, and Yemen, and genotype 6a is predominant in Chi-
na. The HCV genotype 3a is predominant in Pakistan and 
India. The HCV genotype 1a is the predominant subtype in 
Iran, despite a high number of visitors from and to Arab 
countries, in which genotype 4 has been identified as the 
predominant subtype, and also the fact that Iran has a 
border with Tajikistan and Turkmenistan in the north, 
in which genotype 1b appears as the major subtype (3). 
Gene sequencing studies identified six major genotypes 
and more than 100 subtypes of HCV (4, 5). The HCV geno-
types 1, 2, and 3 are the most commonly observed geno-
types worldwide (6). The HCV genotype 1b is the most 
common genotype detected in HCV-infected patients 
in Turkey (6, 7). The identification of genotypes, prior to 
therapy, is particularly important, due to the fact that 
therapies may vary depending on the genotypes involved 
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(2, 3). The distribution of the HCV genotype exhibits geo-
graphic variations around the world, and the knowledge 
of the distribution of genotypes in a particular country, 
as well as in a particular region of the country, are essen-
tial for tailoring appropriate treatment strategies (8). The 
studies conducted in Turkey identified HCV genotype 1 
as the predominant subtype, and the studies reported a 
lower frequency for genotype 3. The genotypes identified 
in Turkey do not exhibit age and gender difference. In 
contrast to previous reports, the present study showed a 
prevalence rate for genotype 1 below the average of Turk-
ish data and a prevalence rate for genotype 3 above the 
average of Turkish data.
2. Objectives
The aim of the present study was to determine the dis-
tribution of HCV genotypes across geographic regions 
and compare these data with those obtained from other 
geographic locations.
3. Patients and Methods
3.1. Sample Selection
The province of Kahramanmaras is divided into nine 
districts, with a total population of 1000000. The study 
hospital is a state hospital and the largest central hospi-
tal in the province. Between March 2010 and August 2014, 
the study included samples from the general population 
and subjects with the suspicion of illicit drug use, who 
are placed on probation, during which they are subjected 
to regular urine drug testing, as mandated by the pros-
ecution office, under the supervision of a psychiatrist, for 
the purpose of resettlement. At our hospital, HCV RNA 
and HCV genotypes are regularly tested in samples from 
HCV-positive patients from the general population and 
subjects on probation delivered from the city center and 
nine districts of the province. Accordingly, the presence 
of HCV RNA was investigated in 2736 samples from anti-
HCV positive patients. An HCV genotype analysis was per-
formed in 313 patients with HCV-RNA positivity. The local 
ethics committee approved the study with an issue num-
ber 3, dated May 26, 2015. Informed consent was obtained 
from the patients who underwent urine drug testing.
3.2. Hepatitis C Virus RNA Analysis
The sera separated from the blood samples dispatched 
to our laboratory, with the diagnosis of HCV, were stored 
at -80°C until analysis. The samples were warmed to room 
temperature before analysis. Viral DNA was extracted us-
ing a commercial extraction kit (QIAsymphony DSP Vi-
rus/Pathogen Midi Kit, QIAGEN, Hilden, Germany). Quan-
tification of HCV RNA was performed using ArtusHCV 
QS-RG Q Kit (QIAGEN, Hilden, Germany) and the real-time 
polymerase chain reaction (RT-PCR) method in the Rotor-
Gene RG-Q (QIAGEN, Hilden, Germany) device.
3.3. Genotyping in HCV RNA Positive Serum Sam-
ples
The HCV genotype was tested using the RT-PCR method 
as per the manufacturer’s instruction. Genotypes 1/2/3/4 
were analyzed. Genotyping was performed in serum 
samples obtained from 313 patients that were found to be 
positive for HCV-RNA. The sera were stored at -80ºC, until 
the day of analysis. The samples were warmed to room 
temperature before analysis. The HCV genotype analysis 
was performed using GenoSen’s HCV Genotyping 1/2/3/4 
RT-PCR Reagents Kit (Genome Diagnostics, New Delhi, In-
dia). For each reaction, 7.5 μL HCV Genotyping Super Mix 
(R1) were mixed with 2.5 μL of HCV Genotyping Mg solu-
tion (R2) and 15 μL of patient serum. After 10 minutes of 
a single cycle at 95°C in the Rotor-RG-Q (QIAGEN, Hilden, 
Germany), 45 cycles were completed (15 sec at 95°C, 20 
seconds at 55°C, and 15 seconds at 72°C).
3.4. Urine Drug Test
The presence of amphetamines (i.e. captagon, Ritalin, 
Dexedrine, and ecstasy), cocaine, opiates (i.e. morphine, 
codeine, heroin, oxycodone, fentanyl, and methadone) 
and cannabinoids (THC and cannabis) were investigated 
in urine samples from patients who were on supervised 
release. All these tests were performed using Roche/Hi-
tachi Cobas c501 device (Roche/Hitachi, Indianapolis, IN, 
USA). Amphetamine was tested with an Amphetamines II 
(AMPS2) kit, cocaine was tested with a Cocaine II (COC2) 
kit, opiates were tested with an Opiates II (OPI2) kit, and 
cannabinoids were tested with a Cannabinoids II (THC2) 
kit (9, 10).
4. Results
Between March 2010 and May 2014, HCV genotype analy-
sis was performed on a group of 313 patients, which in-
cluded 212 males (67.7%) and 101 females (32.2%). The mean 
age of the patients was 41.29 ± 20.32 years. The HCV geno-
type 1 favored female gender, affecting 56.7% of women, 
with a mean age of 60.4 years. The HCV genotype 3 fa-
vored the male gender, affecting 95.8% of men, and the 
mean age was 25 years. The age distribution and mean 
age, according to the genotypes, are presented in Table 1. 
The mean viral load was 1.6 × 106 IU/mL, for genotype 1, 
and 2.1 × 106 IU/mL, for genotype 3. The mean HCV RNA 
load of the patients was 1.9 × 106 IU/mL. In terms of HCV 
genotype distribution, 162 patients (51.7%) had genotype 
1, 144 patients (46%) had genotype 3, four patients (1.3%) 
had genotype 2, and three patients (1%) had genotype 4. 
As depicted in Figure 1, the prevalence of genotype 1 de-
clined and the prevalence of genotype 3 increased over 
the years. The individuals convicted of illicit drug offens-
es in Turkey are placed on probation, during which they 
are subjected to urine drug testing every 3 weeks, as man-
dated by the prosecution office, under the supervision of 
police, after providing consent for the test. After the ret-
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rospective review of 313 patients, the results of urine drug 
tests were available in only 65 (20.2%) patients, 61 (93.8%) 
of which had HCV genotype 3. Other data regarding the 
patients, except age, gender, and place of origin, could 
not be obtained. Of patients possessing a risk factor, only 
65 had a positive history for illicit drug use.
5. Discussion
The HCV genotyping has an important role in the selec-
tion of appropriate therapy, duration of treatment, and 
close monitoring of the response to therapy, in patients 
with chronic hepatitis C infection. The response to inter-
feron therapy, in patients infected with HCV genotypes 1 
and 4, is poorer and the duration of treatment is longer, 
compared to patients infected with genotypes 2 and 3. In 
addition, patients infected with genotype 1b have been re-
ported to have a higher risk of developing hepatocellular 
carcinoma. The HCV genotyping, besides shaping the treat-
ment, also provides information regarding the prognosis 
of the patients (8). Of the 313 patients who were found to 
be positive for HCV RNA, 67.7% were males, who were sig-
nificantly predominant among these patients (P = 0.0001). 
Although other studies conducted in Turkey and Pakistan 
showed no significant difference in terms of gender, the 
results of the present study showed male predominance, 
which was parallel to the findings of a study conducted in 
Iran (79.6%) (11-13). When genotype distribution was evalu-
ated in terms of gender, genotype 3 showed 95.8% male pre-
dominance and type 1 showed 56.7% female predominance. 
The mean age of the patients in our study was 41.29 ± 20.32 
years. This result was consistent with the findings of Had-
inedoushan et al. (13), who reported an age range of 21 - 31 
years for genotype 1a and the predominance of genotype 3 
in all age groups, beyond this age group. The mean age was 
55 years in 161 patients with genotype 1. This finding was 
consistent with the finding of Buruk et al. (11). When the 
mean age was analyzed separately for each year, the mean 
age for type 1 was 48 years in 2010, 54 years in 2011, 60 years 
in 2012, 60 years in 2013, and 62 years in 2014. There was an 
increase in the mean age, between 2010 and 2014. The mean 
age was 25 years in 138 patients with genotype 3. There was 
an increase in the mean age for type 3, when it was analyzed 
separately for each year. The mean viral load for HCV RNA 
was 1.9 × 106 IU/mL. There was no significant correlation be-
tween viral load for HCV RNA and HCV genotype. Likewise, 
Hadinedoushan et al. (13) did not report any relationship 
between viral load and genotype. The genotype distribu-
tion pattern in Turkey shows the predominance of geno-
type 1 (57.6 - 100%). In general, genotype 1 is more common 
in the interior regions and it is reported to be less common 
in large cities and in those allowing the flow of immigrants 
(7, 11, 14-24). The studies related to HCV genotype distribu-
tion in Turkey are presented in Table 2 Figure 2.
Table 1.  Distribution of Patients According to Gender and 
Mean Age a
Genotype Sample Size Mean Age, y
Female Male Female Male
1 92 (56.7) 70 (43.2) 60.44 51.43
2 - 4 (100) - 40
3 6 (4.2) 138 (95.8) 31.4 25
4 2 (66.6) 1 (33.3) 24 25
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type 1 (n=162)
type 2  (n=4)
type 3 (n=144)
type 4 (n=3)
Figure 1. The Percent Distribution of Genotype Over the Years
Table 2.  The Studies Related to HCV Genotype Distribution in Turkey
Studies in Turkey Year Genotypes (%) Reference
1 1a 1b 2 3 4
Bozdayi et al. 2004 11 84 3 3 1 (14)
Selcuk et al. 2006 24.6 68.5 7 (15)
Altuglu et al. 2008 9.9 87.2 0.9 1.4 0.6 (7)
Sanlidag et al. 2009 2 90 2 5 (16)
Kucukoztas et al. 2010 1.9 76.9 3.8 9.6 1.9 (17)
Celik et al. 2010 8.99 88.20 1.12 1.69 (18)
Karsligil et al. 2011 9.8 78.4 7.8 2 2 (19)
Gokahmetoglu et al. 2011 3.4 52.7 2.7 0 35.6 (20)
Kayman et al. 2012 2.4 57.6 3.2 1 32 (21)
Rota et al. 2013 3.1 86.3 6.2 2.1 2.1 (22)
Buruk et al. 2013 5.3 87.5 1.6 4.9 0.7 (11)
Tezcan et al. 2013 1.7 84.7 0.4 4.2 0.8 (23)
Current Study 2014 51.7 1.3 46 1
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Figure 2. Current Data of HCV Genotype Distribution Geographical map of the Cities in Turkey
In the present study that was conducted in the province 
of Kahramanmaras, which has a population of 1 million 
people and is located in the Mediterranean region, the 
prevalence of genotype 1 was 51.7% and the prevalence 
of genotype 3 was 46%, which differed from the coun-
try data. Consistent with the data from other regions 
in Turkey, the prevalence of genotype 2 was 1.3% in the 
present study. High prevalence rates have been reported 
for genotype 4, which is mostly reported in the Middle 
East, in Kayseri and Afyon provinces, in Turkey (21, 25). 
The prevalence of genotype 4 was found to be 1% in the 
present study, which is consistent with other studies. 
The analysis of yearly distribution revealed interesting 
findings. Genotype 1 was the predominant type in years 
2010 and 2011 (76% and 65%, respectively), and this rate de-
clined to 36% and lost its predominance in 2012. The HCV 
genotype 3 has a low countrywide prevalence in Turkey 
(1-3%) (7, 11, 14, 16-19, 21-23). The highest prevalence rate was 
reported by Kucukoztas et al. (17), as 9.6%. Different from 
the other studies reported in other regions, the preva-
lence of HCV genotype 3 was 46%, which was a very high 
prevalence rate that has not been previously reported. 
When the study data were analyzed separately for each 
individual year, the 76% prevalence rate for genotype 1 
in 2010 declined to 36% in 2013, and, in contrast, the 24% 
prevalence rate for genotype 3 in 2010 increased to 62% in 
2013 and become the predominant genotype. We suggest 
that intravenous drug use may have become more com-
mon among young males, and this may have led to an 
increase in the prevalence of genotype 3 in Kahramanma-
ras City. However, further studies are required to confirm 
the increase in the prevalence. Genotype distribution 
across years is presented in Figure 2. It can be argued that 
genotype 3 in the southern region of Turkey is becom-
ing more prevalent, when compared to the prevalence 
rate in other regions. The response to therapy is better 
in genotype 3, when compared to genotype 1; however, 
genotype 3 has clinical significance due to its associa-
tion with hepatosteatosis and accelerated liver fibrosis, 
in the case of chronic disease, and early therapy is es-
sential for better prognosis (8). We consider that further 
studies must be conducted to determine the causes for 
increasing prevalence of genotype 3 in the southern re-
gion of Turkey, which is different from the other regions. 
In the Turkish justice system, those who are arrested or 
sentenced to prison for the crimes they have committed
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Table 3.  Distribution of HCV Genotypes and Illicit Drugs Detected in Patients who Have Been Placed on Probation
Drugs Type 1 Type 2 Type 3 Type 4
Opiates positive, iv 1 - 24 -
Cannabinoids/Amphetamines/Cocaine positive, oral 1 - 12 -
History of opiates use, iv - - 15 -
History of Cannabinoids/ Amphetamines/Cocaine use, oral 1 - 10 1
Total 3 61 1
can be placed on supervised release within the commu-
nity, under which the parolee is considered to be serving 
his/her sentence under custody and supervision, instead 
of serving prison sentence. In this scope, individuals who 
are convicted of illicit drug offenses are subjected to urine 
drug testing every 3 weeks, by the prosecution office, un-
der the supervision of the police, after providing consent 
(26). Genotype 3 is more common among intravenous 
drug users and young people (27-31). Based on these data, 
313 patients were retrospectively reviewed for the avail-
ability of urine drug testing in the scope of supervised re-
lease, to investigate the reasons for increased prevalence 
of genotype 3, which became the predominant type over 
years. The results of urine drug tests were available in only 
65 patients (20.2%). As explained in Table 3 in detail, 61 of 65 
patients (93.8%) had HCV genotype 3. The mean age of the 
patients with HCV genotype 3 was 25 years and the fact that 
95.8% of these patients were males suggested that other pa-
tients, for whom urine drug tests were not available, were 
also illicit drug users. However, this presumption requires 
support from further comprehensive studies.
The HCV genotypes show different distribution patterns 
in different parts of the world (32-35). Attaullah et al. (12) 
examined genotype distribution in 28400 HCV-infected 
individuals studied in 34 different trials in Pakistan, and 
reported a prevalence rate of 78.96% for genotype 3, 7.03% 
for genotype 1, 3.81% for genotype 2, 1.59% for genotype 4, 
0.10% for genotype 5, 0.13% for genotype 6, and 5.03% for 
mixed genotypes. Furthermore, they did not report dif-
ferences between HCV genotypes, in terms of age and 
gender. Other studies have also reported findings sup-
porting these results (36-38). However, the studies in the 
US and Asia reported that genotype 3 was associated with 
young age, particularly with intravenous drug users, 
tattooing, and piercing. Outbreaks have been reported 
among intravenous drug users, as a result of shared use of 
injectors and needles (27-31, 37). Hadinedoushan et al. (13) 
reported a prevalence rate of 50% for HCV genotype 3, 38% 
for genotype 1a, 6.8% for genotype 1b, and 1.6% for geno-
type 2. Zhang et al. (39) studied HCV-infected intravenous 
drug users in China and reported a prevalence rate of 47% 
for genotype 6 and 41% for genotype 3. Sanders-Buell et al. 
(40) reported a prevalence rate of 62% for genotype 3 and 
35% for genotype 1 among HCV-infected intravenous drug 
users in Afghanistan. The limitation of the present study 
was that urine drug tests were conducted on only 65 of 
the 313 patients.
In conclusion, the present study revealed data regard-
ing the distribution of HCV genotypes over a period of 
4 years in the province of Kahramanmaras, which is lo-
cated in the southern part of Turkey. The main difference 
of the present study from other reports in Turkey is that 
the prevalence of HCV genotype 1 declined and the preva-
lence of HCV genotype 3 increased over the years in Tur-
key, to become the predominant genotype, and the preva-
lence rate for genotype 3 is the highest rate ever reported 
for this genotype in the literature.
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